Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt Inc (ADTX) is a pioneering biotechnology company developing innovative solutions to reprogram immune responses, with applications in organ transplantation and autoimmune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic partnerships.
Access authoritative reporting on ADTX's flagship programs including Adimune for transplant tolerance and AditxtScore diagnostic platforms. Track developments in Apoptotic DNA Immunotherapy (ADi) and other novel approaches to immune modulation. The curated news feed covers earnings reports, research collaborations, and product pipeline updates while adhering to financial disclosure standards.
Bookmark this page for consolidated access to press releases, clinical trial data disclosures, and expert analyses of ADTX's position in the competitive immunotherapy landscape. Stay informed about technological breakthroughs through verified updates from primary sources.
Aditxt, Inc. (NASDAQ: ADTX) has successfully closed a registered direct offering with a healthcare-focused institutional investor, selling 1,585,350 shares of common stock at $1.22 per share. The gross proceeds from this transaction amount to approximately $1.9 million, excluding fees and expenses. In addition, the company issued warrants for 3,170,700 shares at an exercise price of $0.86, valid for three years. The proceeds will be utilized for working capital and other corporate purposes. The offering was conducted under an effective shelf registration statement and complies with SEC regulations.
Aditxt is focused on technologies to monitor and modulate the immune system, with an emphasis on developing treatments for organ rejection, autoimmunity, and infectious diseases.
Aditxt, Inc. (NASDAQ: ADTX) has announced a definitive agreement with a healthcare-focused institutional investor to sell 1,585,350 shares of common stock at $1.22 each in a registered direct offering. Additionally, unregistered warrants to purchase 3,170,700 shares at an exercise price of $0.86 will be issued. The offering is expected to close around April 24, 2023, pending customary closing conditions. Gross proceeds are projected at $1.9 million, intended for working capital and corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent.
Aditxt, Inc. (NASDAQ: ADTX) has signed an asset purchase agreement with Cellvera, granting Aditxt a 50% stake in Global Response Aid (GRA), a partnership with Agility. The deal involves a total transaction value of $24.5 million, which includes the forgiveness of a $14.5 million loan and $10 million in cash, alongside future royalties over seven years. This strategic acquisition aims to expand Aditxt’s capabilities in developing effective antiviral therapies, particularly focusing on the drug Avigan, which is licensed for use in multiple markets excluding Japan, China, and Russia. The agreement is contingent upon various approvals, including board and regulatory consents. Aditxt's CEO emphasizes that this acquisition is pivotal for driving future growth and addressing the rising demand for antiviral solutions.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
